By Billy Candra 
A groundbreaking advancement in neuro-oncology, spearheaded by a collaborative team of scientists at the University of Nottingham and clinicians at Nottingham University Hospitals NHS Trust (NUH), promises to revolutionise the diagnosis and treatment pathway for brain tumour patients across the United Kingdom. This novel method drastically reduces the diagnostic turnaround time from an arduous 6-8 weeks to an unprecedented two hours, offering a beacon of hope for individuals grappling with one of the most aggressive and complex forms of cancer.
The Urgent Need for Expedited Diagnosis
Brain tumours represent a formidable challenge in modern medicine. Each day, an estimated 34 people in the UK receive a brain tumour diagnosis, contributing to over 12,000 new cases annually. The landscape of brain cancer is diverse, ranging from benign to highly malignant forms, with some aggressive types, such as glioblastoma multiforme, carrying an average survival rate of less than a year. The critical window for effective intervention in these cases is often narrow, making rapid and accurate diagnosis paramount.
Historically, the diagnostic process for brain tumours has been protracted and fraught with challenges. Following initial imaging (typically an MRI scan) to identify a suspected tumour, patients undergo surgery to obtain a tissue sample. This sample is then sent to centralised analysis facilities for complex genetic testing. This crucial step, which determines the specific type of tumour and informs prognosis and treatment strategies, traditionally involves a waiting period of 6-8 weeks, sometimes even longer, for full results.
This extended delay carries significant consequences. For patients and their families, the weeks spent awaiting a definitive diagnosis are an emotionally harrowing period, marked by intense anxiety and uncertainty. Clinically, this waiting time can critically impede the initiation of vital treatments such as radiotherapy and chemotherapy. Delayed treatment, particularly for fast-growing and aggressive tumours, can diminish the chances of success, potentially impacting patient outcomes and overall survival rates. The existing system, while thorough, was not designed for the speed demanded by the aggressive nature of many brain cancers, leaving a significant gap in patient care.
A Paradigm Shift: The Nottingham Method
The newly developed ultra-rapid genetic diagnosis method directly addresses this critical delay. Detailed in a study published today in the prestigious journal Neuro-Oncology, this innovation stems from years of dedicated research and interdisciplinary collaboration. The core of the method lies in its ability to quickly and accurately perform complex genetic analyses that previously required extensive processing time.
The team at NUH has already put this new approach to the test, utilising it during 50 brain tumour surgeries. The results have been unequivocally positive, demonstrating a 100% success rate in providing diagnostic results within two hours of surgery. Furthermore, detailed tumour classifications were available within minutes of sequencing. The platform’s robust capabilities extend beyond this immediate analysis, allowing for a fully integrated diagnosis to be completed within 24 hours, offering comprehensive molecular insights.
Dr. Stuart Smith, a distinguished Neurosurgeon from the School of Medicine at the University of Nottingham and NUH, highlighted the transformative potential. "Traditionally, the process of diagnosing brain tumours has been slow and expensive," Dr. Smith explained. "Now, with this new technology, we can do more for patients because we can get answers so much more quickly, which will have a much bigger influence on clinical decision-making, in as little as two hours. Patients find waiting many weeks for results extremely difficult, and this adds to the anxiety and worry at what is already a very difficult time." He further elaborated on the unprecedented possibility of informing surgical strategy in real-time: "This type of operation can be quite long, so potentially, a surgeon could be informed during surgery of the accurate diagnosis, which would then impact on the surgical strategy." This intraoperative diagnostic capability is a revolutionary concept, offering surgeons the ability to tailor their approach based on precise tumour characteristics, potentially leading to more targeted resections and improved patient outcomes.
Technological Ingenuity: Nanopore Sequencing and ROBIN
The technological backbone of this innovation is rooted in advanced genetic sequencing techniques. Professor Matt Loose, a biologist from the School of Life Sciences at the University of Nottingham, played a pivotal role in developing the methodology. Professor Loose devised a technique to sequence specific parts of human DNA at higher depth using portable sequencing devices manufactured by Oxford Nanopore Technologies. These devices leverage nanopore sequencing, a third-generation technology that offers real-time, high-throughput DNA and RNA sequencing.
Unlike traditional sequencing methods that can be time-consuming and require large, expensive laboratory infrastructure, nanopore sequencers detect changes in electrical current as individual DNA molecules pass through tiny protein nanopores embedded in a membrane. This allows for rapid data acquisition. Professor Loose’s method specifically enables the examination of relevant parts of the human genome much more quickly, by simultaneously sequencing multiple regions of DNA, thereby accelerating the entire diagnostic process.
The team has successfully applied this advanced method to genetically test brain tumour samples. Central to their workflow is ROBIN, a specialised software tool developed for use with P2 PromethION nanopore sequencers. ROBIN processes the raw sequencing data, enabling the rapid identification of critical genetic markers.
Professor Loose reflected on the journey of genetic sequencing: "When we first were able to sequence an entire human genome in 2018, it took around five labs and six months to do, which obviously isn’t ideal when time is of the essence for a patient." He continued, "This new method now allows us to choose the bits of DNA that we need to look at in order to answer specific questions, such as what type of tumour and how can it be treated. Combined with our later research where we were able to look at relevant parts of the human genome more quickly — then we now have a process where we can use ROBIN to create comprehensive classifications of tumours more quickly."
A key focus of this rapid analysis is DNA methylation. Methylation patterns are epigenetic modifications that do not alter the DNA sequence itself but play a crucial role in gene regulation and cellular identity. In cancer, aberrant methylation patterns are often highly indicative of tumour type and can even predict response to certain therapies. "Once we have a sample from a patient, we can now quickly extract the DNA and look at the different properties to give us the information we need. Methylation is the one we are most interested in early on in this instance because that defines the tumour type," Professor Loose explained, underscoring the precision and specificity of the new diagnostic approach.
From Lab to Clinic: A Collaborative Success
The successful implementation of this method is a testament to the power of interdisciplinary collaboration. The journey from Professor Loose’s biological innovation to its clinical application involved seamless coordination between university researchers and hospital clinicians. Once a tumour sample is removed during surgery, it is immediately sent to the pathology lab at NUH, where DNA is rapidly extracted before being transferred to Professor Loose’s team for sequencing and analysis. This integrated workflow ensures minimal delay from surgical removal to diagnostic insight.
Dr. Simon Paine, a Consultant Neuropathologist at NUH, echoed the sentiments of his colleagues, describing the development as a "game changer." "This new method of diagnosing brain tumours is going to be a game changer, it really is revolutionary. It not only increases the speed at which the results will be available, but the degree of accuracy of the diagnosis as well is incredible." The shift from traditional histopathological examination (visual identification of cells) to precise molecular classification has been a significant evolution in neuropathology over the last few years, and this rapid sequencing method accelerates that evolution exponentially. The ability to identify genetic and epigenetic abnormalities quickly provides a far more accurate and nuanced understanding of the tumour than traditional methods alone, leading to more informed and personalised treatment decisions.
Broader Impact and Future Horizons
The implications of this ultra-rapid diagnostic method extend far beyond the immediate benefits of speed and accuracy. Its potential to transform patient care, healthcare economics, and the landscape of cancer research is substantial.
Patient-Centred Care: The most immediate and profound impact will be on patients. Reducing the diagnostic wait time from months to hours will alleviate immense psychological distress. Patients will receive definitive answers much faster, enabling them and their families to make informed decisions about treatment pathways and future planning without prolonged uncertainty. This rapid classification also facilitates the prompt commencement of targeted therapies, which is particularly critical for aggressive tumours where every day counts.
Clinical Decision-Making: The potential for intraoperative diagnosis empowers surgeons with real-time molecular information, allowing for dynamic adjustments to surgical strategy. This could lead to more complete resections of cancerous tissue or guide decisions on the extent of tissue removal, minimising damage to healthy brain tissue while maximising tumour removal. Post-surgery, the rapid comprehensive diagnosis ensures that adjuvant treatments like chemotherapy and radiotherapy can begin without delay, optimising their efficacy.
Healthcare Economics: Beyond improving patient outcomes, the new method also presents significant economic advantages. Professor Loose noted, "Not only is the test more accurate and quicker, but it is also cheaper than current methods." He estimated the cost at approximately £450 per person, with potential for further reduction when scaled up. This cost-effectiveness stems from the method’s ability to consolidate multiple separate tests into one comprehensive analysis. "Our method can eliminate the need for four to five separate tests, reducing costs as a consequence as we are getting more information from the single test we do. Most importantly, it delivers results to the patients when they need them," Professor Loose stated. This economic efficiency could make advanced molecular diagnostics more accessible across the NHS, potentially reducing overall healthcare expenditure associated with prolonged hospital stays and delayed, less effective treatments.
Equity of Access and National Rollout: The Nottingham team is now actively pursuing the rollout of this new testing method across NHS Trusts throughout the UK. This ambition addresses a critical issue of healthcare equity. Centralised, expensive, and slow diagnostic facilities can inadvertently create disparities in access for patients in different regions. A localised, rapid, and cheaper test has the potential to democratise access to state-of-the-art molecular diagnostics, ensuring that all patients, regardless of their geographical location, can benefit from the highest standard of care.
Dr. Simon Newman, Chief Scientific Officer at The Brain Tumour Charity, underscored this point: "The delivery of an accurate diagnosis within hours of surgery will be transformative for all patients, ensuring rapid access to the optimal standard of care and — crucially — removing the uncertainty patients face when having to wait weeks for their diagnosis and prognosis." He added, "The potential to combine so many separate tests into one and deliver at a localised level is a game changer for driving equity of access to rapid and accurate molecular diagnosis."
Advancing Research and Personalised Medicine: The rapid diagnostic platform also holds immense promise for accelerating brain tumour research and the development of personalised medicine. By quickly and accurately classifying tumours, researchers can more efficiently stratify patients for clinical trials. The Brain Tumour Charity, through its funding of the BRAIN MATRIX Trial, is already exploring how this technology can match patients to personalised clinical trials across the UK. This will facilitate faster drug discovery, validation of new therapies, and ultimately, a more tailored approach to treating individual patients based on the unique genetic profile of their tumour.
In conclusion, the development from the University of Nottingham and Nottingham University Hospitals NHS Trust represents a monumental leap forward in the fight against brain tumours. By collapsing diagnostic timelines and enhancing accuracy, this ultra-rapid genetic sequencing method is poised to fundamentally reshape patient care, reduce suffering, and pave the way for a new era of personalised and effective treatments for thousands of patients every year. The journey from research bench to nationwide implementation is challenging, but the proven success and profound benefits demonstrated thus far signal a brighter future for brain tumour patients in the UK and potentially, worldwide.
